VYNE Therapeutics Earnings Perspective: Return On Capital Employed

By: via Benzinga
VYNE Therapeutics (NASDAQ:VYNE) brought in sales totaling $126 thousand during Q2 according to data provided by Benzinga Pro. However, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.